サンプル依頼リスト カート
  • English
  • Korean
表紙：アフェレーシスの世界市場-2023年～2030年
市場調査レポート
商品コード
1347967

アフェレーシスの世界市場-2023年～2030年

Global Apheresis Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
アフェレーシスの世界市場-2023年～2030年
出版日: 2023年09月11日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界のアフェレーシス市場は2022年に18億米ドルに達し、2023-2030年の予測期間中にCAGR 8.4%で成長し、2030年には50億米ドルに達すると予測されています。

アフェレーシスとは、人の血液から特定の成分を分離、抽出、採取する医療技術の医療手順です。装置の発売数の増加と血液疾患の増加が市場成長の原動力になると予想されます。

北米地域が市場シェアで大きな位置を占めると予想されます。プラズマフェレーシス部門が大きな市場シェアを占めています。デバイスの技術的進歩の増加とその利点が、このセグメントを重要な位置に保持しています。

DataM Intelligenceによると、アフェレーシス市場の調査分析は、定量的および定性的データを含む市場の詳細な見通しを提供します。市場セグメンテーションに基づく世界市場の展望と予測を提供します。

ダイナミクス

デバイス上市数の増加が市場成長を牽引する見込み

デバイスの上市数の増加が市場成長を促進すると予想されます。例えば、医療技術企業のテルモ・ブラッド・アンド・セル・テクノロジーズ（Terumo BCT）は2022年9月20日、細胞・遺伝子治療（CGT）分野のプロセス開発から商業生産までをサポートするバイオリアクタープラットフォーム「Quantum Flex Cell Expansion System」を発表しました。

さらに、例えばテルモ・ブラッド・アンド・セル・テクノロジーズは2023年8月1日、血液を1回の遠心分離で血小板に加工するレヴェオス装置を発売し、米国食品医薬品局（FDA）の認可を取得しました。このように、上市数の増加が市場成長の原動力になると予想されます。

血液疾患の増加が市場成長を牽引すると予想される

血液疾患の増加が市場成長の原動力になると予想されます。例えば、CDCによると、鎌状赤血球症は約10万人の米国人が罹患しています。鎌状赤血球症は、黒人またはアフリカ系米国人の出生365人に1人の割合で発症します。ヒスパニック系米国人の出産では16,300人に1人の割合で発症します。黒人またはアフリカ系米国人の赤ちゃんの約13人に1人が鎌状赤血球形質（SCT）を持って生まれます。

赤血球交換は、脳卒中や急性胸部症候群などの鎌状赤血球症の重篤な合併症の治療や予防に用いられます。赤血球交換では、病気や異常のある赤血球をアフェレーシスで除去し、ドナーの赤血球と交換します。さらに、米国がん協会による2023年の米国における白血病の推計は、白血病（全種類）の新規患者数約59,610人、白血病（全種類）による死亡者数23,710人、急性骨髄性白血病（AML）の新規患者数20,380人です。白血球アフェレーシスは、循環血液から患者の白血球を除去するものです。したがって、血液疾患の増加

アフェレーシスに伴う高コストが市場成長の妨げになると予想される

これらの処置のコストが高いことも、市場の成長を抑制する大きな要因です。例えば、プラズマフェレーシスの平均コストは、1回の処置につき1,500米ドルから2,500米ドルの間です。アフェレーシスの手技には様々なリスクが伴いますが、中でも重要なのは血液の汚染で、これは手技中に非常によく見られます。

アフェレーシスに伴うその他の合併症も、市場の成長に影響を与える可能性があります。最も一般的なアフェレーシス特有の反応は、クエン酸塩抗凝固療法による低カルシウム血症で、通常は軽度ですが、ドナーに深刻な損傷を与える可能性があります。アフェレーシス投与を繰り返すと、骨脱灰や白内障形成などの長期的な悪影響がドナーに生じる可能性があります。したがって、上記の要因は市場の成長を妨げると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • デバイス上市数の増加
      • 血液疾患の増加
    • 抑制要因
      • アフェレーシスに伴う高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 デバイス別

  • アフェレーシス装置
  • 血漿分離装置
  • 血漿成分分離装置
  • 免疫吸着カラム
  • 血漿灌流カラム
  • 血液灌流カラム
  • アフェレーシス用消耗品

第8章 技術別

  • 遠心分離
  • 間欠フロー
  • 連続フロー
  • 膜分離

第9章 手技別

  • プラズマフェレーシス
  • 血小板アフェレーシス
  • 赤血球アフェレーシス
  • 白血球アフェレーシス
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Fresenius SE & Co. KGaA
    • 企業概要
    • デバイス・ポートフォリオと概要
    • 財務概要
    • 主な動向
  • Cerus Corporation
  • Asahi Kasei Medical Co., Ltd.
  • Haemonetics Corporation
  • B. Braun Melsungen
  • Kaneka Corporation
  • Terumo BCT, Inc.
  • Kawasumi Laboratories Inc.
  • Nikkiso Europe GmbH
  • Baxter.

第13章 付録

目次
Product Code: MD2202

Overview

Global Apheresis Market reached US$ 1.8 billion in 2022 and is expected to reach US$ 5.0 billion by 2030, growing with a CAGR of 8.4% during the forecast period 2023-2030.

Apheresis is a medical technology medical procedure that involves the separation, extraction, and collection of specific components of a person's blood. The increased number of launches of the devices and an increase in hematological disorders are expected to drive market growth.

North America region is expected to hold a significant position in the market share. The plasmapheresis segment holds a significant market share. The increase in technological advancements in the Devices and their advantages are holding the segment in a significant position.

As per DataM Intelligence, Apheresis Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation.

Dynamics

Increased Number of Device Launches is Expected to Drive the Market Growth

An increased number of Device launches are expected to drive the market growth. For instance, on September 20, 2022, Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, launched its Quantum Flex Cell Expansion System, a bioreactor platform that supports process development through to commercial manufacturing for the cell and gene therapy (CGT) sector.

Additionally, for instance, on August 1, 2023, Terumo Blood and Cell Technologies launched a Reveos device that processes blood into platelets in a single centrifugation cycle, which has been cleared by the US Food and Drug Administration (FDA). Thus, an increase in the number of launches is expected to drive the market growth.

Increase in Hematological Disorders is Expected to Drive Market Growth

An increase in hematological disorders is expected to drive market growth. For instance, according to the CDC, Sickle Cell Disease affects approximately 100,000 Americans. SCD occurs among about 1 out of every 365 Black or African-American births. It occurs among about 1 out of every 16,300 Hispanic-American births. About 1 in 13 Black or African-American babies is born with sickle cell trait (SCT).

Red blood cell exchange is used to treat or sometimes prevent serious complications of sickle cell disease, such as stroke and acute chest syndrome. In red blood cell exchange, diseased or abnormal red blood cells are removed by apheresis and then replaced by donor red blood cells. Additionally, The American Cancer Society's estimates for leukemia in the United States for 2023 are about 59,610 new cases of leukemia (all kinds) and 23,710 deaths from leukemia (all kinds), 20,380 new cases of acute myeloid leukemia (AML). Leukapheresis involves the removal of a patient's white blood cells from the circulating blood. Thus, the increase in hematological disorders

High costs Associated with Apheresis are Expected to Hamper the Market Growth

The high cost of these procedures is also a big factor restraining the growth of the market. For instance, the average cost of plasmapheresis ranges between $1,500 and $2,500 per procedure. Various risks are associated with the Apheresis procedure, and the crucial one is blood contamination, which is very common during the procedure.

Other complications with the apheresis can also affect the market growth. The most common apheresis-specific reaction is hypocalcemia due to citrate anticoagulation, which, while usually mild, has the potential to injure the donor severely. Repeated apheresis donation may produce adverse long-term effects in donors, such as bone demineralization and cataract formation. Thus, the above factors are expected to hamper the market growth.

Segment Analysis

The global apheresis market is segmented based on device, technology, procedure, and region.

Centrifugation Segment Holds a Significant Position in the Market Share

Centrifugal apheresis can be used to remove cellular components and is very efficient, achieving plasma extraction of nearly 80%. One of the benefits of centrifugal apheresis is that it requires lower blood flow rates and, therefore, can be performed using either peripheral or central venous access.

Most apheresis devices use centrifugation and require blood flow rates of 50-120 mL/min. Centrifugation takes advantage of the different specific gravities inherent to various blood products, such as red blood cells (RBCs), white blood cells (WBCs), platelets, and plasma. Thus, the advantages and efficiency of the centrfugation in seperating the whole blood components is holding a dominant position in the market share.

Geographical Penetration

North America region holds the largest market share in the global Apheresis market

North America holds a significant share of the global apheresis market. The increase in the number of blood transfusions and the increase in the demand for various blood components are holding the region's market growth. For instance, according to the American National Red Cross, approximately 29,000 units of red blood cells are needed every day in the U.S., nearly 5,000 units of platelets and 6,500 units of plasma are needed daily in the U.S., and about 16 million blood components are transfused each year in the U.S.

Additionally, according to the American Cancer Society, more than 1.9 million people are expected to be diagnosed with cancer in 2023. Many of them will need blood, sometimes daily, during their chemotherapy treatment. Thus, an increase in the demand for blood transfusions in the region is expected to hold the region in the dominant position.

Competitive Landscape

The global apheresis market is fragmented, with the presence of many local and international players. Fresenius SE & Co. KGaA, Cerus Corporation, Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, B. Braun, Melsungen, Kaneka Corporation, Terumo BCT, Inc., Kawasumi Laboratories Inc., and Nikkiso Europe GmbH, Baxter. are the leading Companies with a significant market share.

COVID-19 Impact Analysis

The COVID-19 epidemic is expected to benefit the development of the global apheresis business. Global healthcare systems were under pressure from the COVID-19 epidemic. Due to COVID-19, patients with severe infections had complications with their coagulation parameters, including platelet count, fibrinogen, D-dimer, prothrombin time (PT), and activated partial thromboplastin time (aPTT). As a result, plasma therapy was used extensively as a treatment. Patients who contracted the COVID-19 virus are treated with convalescent plasma (CP).

By Device

  • Apheresis Devices
  • Plasma Separators
  • Plasma Component Separators
  • Immunoadsorption Columns
  • Plasma Perfusion Columns
  • Hemoperfusion Columns
  • Apheresis Disposables

By Technology

  • Centrifugation
  • Intermittent Flow
  • Continuous Flow
  • Membrane Separation

By Procedure

  • Plasmapheresis
  • Plateletpheresis
  • Erythrocytapheresis
  • Leukapheresis
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global apheresis market segmentation based on device, technology, procedure, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of apheresis market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Device mapping available as excel consisting of key Devices of all the major players.

The global apheresis market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Procedure
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased number of device launches
      • 4.1.1.2. Increase in hematological disorders
    • 4.1.2. Restraints
      • 4.1.2.1. High cost associated with apheresis
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
    • 7.1.2. Market Attractiveness Index, By Device
  • 7.2. Apheresis Devices *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Plasma Separators
  • 7.4. Plasma Component Separators
  • 7.5. Immunoadsorption Columns
  • 7.6. Plasma Perfusion Columns
  • 7.7. Hemoperfusion Columns
  • 7.8. Apheresis Disposables

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Centrifugation *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Intermittent Flow
  • 8.4. Continuous Flow
  • 8.5. Membrane Separation

9. By Procedure

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 9.1.2. Market Attractiveness Index, By Procedure
  • 9.2. Plasmapheresis*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Plateletpheresis
  • 9.4. Erythrocytapheresis
  • 9.5. Leukapheresis
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Fresenius SE & Co. KGaA *
    • 12.1.1. Company Overview
    • 12.1.2. Device Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Cerus Corporation
  • 12.3. Asahi Kasei Medical Co., Ltd.
  • 12.4. Haemonetics Corporation
  • 12.5. B. Braun Melsungen
  • 12.6. Kaneka Corporation
  • 12.7. Terumo BCT, Inc.
  • 12.8. Kawasumi Laboratories Inc.
  • 12.9. Nikkiso Europe GmbH
  • 12.10. Baxter.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us